Table 1.
Summary of diagnostic models for GDM.
| Cite No. | Sample size (GDM vs. NGT) | Sample type | Sampling time (weeks) | Markers in a model | AUC |
|---|---|---|---|---|---|
| 31 | 15 vs. 14 | Serum | 24-28 | (1) Fibronectin-SNA and PSG-AAL | 0.85 |
| (2) CRP, adiponectin, SHBG, ratio of hCG to placental lactogen, fibronectin-SNA, and PSG-AAL | 0.97 | ||||
| 37 | 20 vs. 20 | Serum | 12-16 | APOE, F9, FGA, and IGFBP5 | 0.985 |
| 38 | 40 vs. 40 | Urine | 15-20 | CD59 and IL1RA | 0.906 |
| 42 | 105 vs. 105 | Serum | 8-13 | (1) Vitronectin | 0.625 |
| (2) Maternal age, history of diabetes, and vitronectin | 0.806 | ||||
| 47 | 25 vs. 25 | Plasma | 11-13 | (1) TSP-4 | 0.94 |
| (2) CNDP1 | 0.98 |
SNA: Sambucus nigra lectin; PSG: pregnancy-specific glycoprotein; AAL: Aleuria aurantia lectin; CRP: C-reactive protein; SHBG: sex-hormone-binding globulin; hCG: human chorionic gonadotropin; APOE: apolipoprotein E; F9: coagulation factor IX; FGA: fibrinogen alpha chain; IGFBP5: insulin-like growth factor-binding protein 5; CD59: CD59 glycoprotein; IL1RA: interleukin-1 receptor antagonist protein; TSP-4: thrombospondin-4; CNDP1: beta-ala-his dipeptidase.